Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer. Yesterday, May 5, 2015, 84 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $500.00 to $1,572,413.89. Highlighted Stocks Traded by Insiders: Cara Therapeutics (CARA) - FREE Research Report Lewis Michael E, who is Chief Scientific Advisor at Cara Therapeutics, sold 7,262 shares at $10.64 on May 5, 2015. Following this transaction, the Chief Scientific Advisor owned 336,774 shares meaning that the stake was reduced by 2.11% with the 7,262-share transaction. The shares most recently traded at $10.15, down $0.49, or 4.83% since the insider transaction. Historical insider transactions for Cara Therapeutics go as follows:
4-Week # shares sold: 7,262
12-Week # shares sold: 29,524
24-Week # shares sold: 36,786
The average volume for Cara Therapeutics has been 187,800 shares per day over the past 30 days. Cara Therapeutics has a market cap of $238.7 million and is part of the health care sector and drugs industry. Shares are up 4.91% year-to-date as of the close of trading on Tuesday. Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors. Currently, there are 4 analysts who rate Cara Therapeutics a buy, no analysts rate it a sell, and none rate it a hold. Exclusive Offer: Get the latest Stock Analysis on CARA - FREETheStreet Quant Ratings rates Cara Therapeutics as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and notable return on equity. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share and deteriorating net income. Get the full Cara Therapeutics Ratings Report from TheStreet Quant Ratings now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.